Applied Filters
The IP fallout if the UK leaves the EU
The unitary patent and UPC would still go ahead, but what would be the impact for the life sciences sector if the UK voted to leave the EU? Victoria Bentley and Helen Cline of Pinsent Masons investigate.
To dance or not to dance: biosimilar strategies post Amgen v Sandoz
Following the Federal Circuit’s ruling in Amgen v Sandoz, biosimilar applicants should weigh up several factors when deciding whether to opt into the so-called patent dance. Gerard Norton and Michael Montgomery of Fox Rothschild discuss the potential strategies.
Court reports: Warner-Lambert v Sandoz
Sandoz has brought to market its generic pregabalin product with a full label in the UK and a skinny label in France. Varuni Paranavitane of Osborne Clarke reports on court rulings in the UK, and most recently France, on actions brought by Warner-Lambert against Sandoz.
CJEU clarifies rules on combination SPCs
An Advocate General in the Court of Justice of the European Union, Niilo Jääskinen, has clarified how the regulation for supplementary protection certificates should be interpreted concerning medicinal products made with a combination of active ingredients.
Further unravelling the SPC Gordian Knot
The CJEU’s decision in Forsgren has brought greater clarity to the scope of the SPC regulation, including whether a substance is an active ingredient, as Avi Toltzis and Penny Gilbert of Powell Gilbert explain.
SPCs: Questions of validity
The tussle between Teva and Amgen over the latter’s SPC for lipegfilgrastim is still playing out in Denmark’s IP court and may yet be referred to the CJEU. Michael Pitzner-Bruun of law firm Kromann Reumert reports.
SPCs: When a few days makes a difference
An advocate-general at Europe’s highest court has said SPCs should come into effect once an applicant for a marketing authorisation has been notified of that authorisation. This is good news for SPC owners, say Anja Lunze and Paul England of Taylor Wessing.
Warner-Lambert v Actavis: lessons from ‘the case of the year’
The Warner-Lambert v Actavis case concerning second medical use patents has resulted in a carefully considered judgment and there are some clear lessons to be learnt, says Arty Rajendra of Rouse Legal.
SPCs: When a few days makes a difference
An advocate-general at Europe’s highest court has said SPCs should come into effect once an applicant for a marketing authorisation has been notified of that authorisation. This is good news for SPC owners, say Anja Lunze and Paul England of Taylor Wessing.
London calling: the benefits of the UPC’s new home
Aldgate Tower will make an ideal home for the UK division of the UPC, with many advantages for its likely users, says Claire Phipps-Jones of Bristows.
